Markets now watching for guidance from two Chinese biotechs after sponsor of anti-China measure says he will leave Congress early

Leading Chinese drug company estimates $100 million net loss in 2023 as biotech funding slows and Covid related income falls

The U.S. Department of Commerce has removed a pharmaceutical contract manufacturer that supplies ingredients for AstraZeneca’s Covid-19 vaccine from its ‘Unverified List.’

Baidu, Poni.ai roll out driverless taxis in Beijing, Chinese biotech duo invest billions in Singapore plan

The investment is part of a 10-year investment plan for Wuxi Biologics and Wuxi AppTec to grow their R&D and manufacturing capabilities in the Southeast Asian country

Ant-backed MYBank is fined for anti-money laundering violations. Chinese and Singaporean regulators vow to support the ETF connect

The Chinese drugmaker suspended trading of its shares in Hong Kong after its addition to the Commerce Department’s unverified list triggered a record sell-off

Sale will reduce company’s stake in its Hong Kong-listed subsidiary to 55.34%

Chinese pharmaceutical firm gains exclusive rights to commercialize medicines in Greater China

Biotech highflier chooses tax-friendly EU member for first overseas facility

After lottery ahead of WuXi AppTec’s listing, 0.3% of shares not taken up

Chinese pharmaceutical firm gets green light for $910 million IPO at home in a mere 50 days

FDA gives nod after Trogarzo showed strong results for patients with drug-resistant strains of the virus that causes AIDS

Mindray Medical, WuXi Biologics among a new generation of drug and device makers cashing in on rapid growth in China’s healthcare system